Floatz logo

Romidepsin

Primary Systemic Amyloidosis

Roswell Park Cancer InstituteSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Primary Systemic Amyloidosis cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Margarida Magalhaes-Silverman
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
Margarida Magalhaes-Silverman
Phase 2B
Evomela
Margarida Magalhaes-Silverman
Phase 2B
Inno-206
Margarida Magalhaes-Silverman
Phase 2B
PREDNISONE TABLETS
Margarida Magalhaes-Silverman
Phase 2B

View all 24 →

Same molecule, other indications

Romidepsin is also rated in:

Myelodysplastic/Myeloproliferative DiseasesDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Mycosis Fungoides/Sezary SyndromeDormant
BBB
Indicative ·
75 / 100
View asset →
Multiple Myeloma and Plasma Cell NeoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →